These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Biodistribution of p-boronophenylalanine in patients with glioblastoma multiforme for use in boron neutron capture therapy. Elowitz EH; Bergland RM; Coderre JA; Joel DD; Chadha M; Chanana AD Neurosurgery; 1998 Mar; 42(3):463-8; discussion 468-9. PubMed ID: 9526978 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic study of BSH and BPA in simultaneous use for BNCT. Yokoyama K; Miyatake S; Kajimoto Y; Kawabata S; Doi A; Yoshida T; Asano T; Kirihata M; Ono K; Kuroiwa T J Neurooncol; 2006 Jul; 78(3):227-32. PubMed ID: 16557351 [TBL] [Abstract][Full Text] [Related]
10. ESR as a valuable tool for the investigation of the dynamics of EPC and EPC/cholesterol liposomes containing a carboranyl-nucleoside intended for BNCT. Rossi S; Schinazi RF; Martini G Biochim Biophys Acta; 2005 Jun; 1712(1):81-91. PubMed ID: 15904892 [TBL] [Abstract][Full Text] [Related]
11. Tissue disposition of 5-o-carboranyluracil--a novel agent for the boron neutron capture therapy of prostate cancer. Schinazi RF; Hurwitz SJ; Liberman I; Glazkova Y; Mourier NS; Olson J; Keane T Nucleosides Nucleotides Nucleic Acids; 2004; 23(1-2):291-306. PubMed ID: 15043155 [TBL] [Abstract][Full Text] [Related]
12. Neutron capture therapy of a rat glioma using boronophenylalanine as a capture agent. Matalka KZ; Barth RF; Staubus AE; Moeschberger ML; Coderre JA Radiat Res; 1994 Jan; 137(1):44-51. PubMed ID: 8265787 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of pharmacokinetics of 4-borono-2-(18)F-fluoro-L-phenylalanine for boron neutron capture therapy in a glioma-bearing rat model with hyperosmolar blood-brain barrier disruption. Hsieh CH; Chen YF; Chen FD; Hwang JJ; Chen JC; Liu RS; Kai JJ; Chang CW; Wang HE J Nucl Med; 2005 Nov; 46(11):1858-65. PubMed ID: 16269600 [TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of sodium mercaptoundecahydrododecaborate after intravenous injection in rats. Mehta SC; Boudinot FD; Lu DR Drug Metab Dispos; 1995 Dec; 23(12):1368-71. PubMed ID: 8689945 [TBL] [Abstract][Full Text] [Related]
15. Suitability of boron carriers for BNCT: accumulation of boron in malignant and normal liver cells after treatment with BPA, BSH and BA. Chou FI; Chung HP; Liu HM; Chi CW; Lui WY Appl Radiat Isot; 2009 Jul; 67(7-8 Suppl):S105-8. PubMed ID: 19375330 [TBL] [Abstract][Full Text] [Related]
16. Boron neutron capture therapy of brain tumors: enhanced survival and cure following blood-brain barrier disruption and intracarotid injection of sodium borocaptate and boronophenylalanine. Barth RF; Yang W; Rotaru JH; Moeschberger ML; Boesel CP; Soloway AH; Joel DD; Nawrocky MM; Ono K; Goodman JH Int J Radiat Oncol Biol Phys; 2000 Apr; 47(1):209-18. PubMed ID: 10758326 [TBL] [Abstract][Full Text] [Related]
17. Enhanced delivery of boronophenylalanine for neutron capture therapy by means of intracarotid injection and blood-brain barrier disruption. Yang W; Barth RF; Carpenter DE; Moeschberger ML; Goodman JH Neurosurgery; 1996 May; 38(5):985-92. PubMed ID: 8727825 [TBL] [Abstract][Full Text] [Related]
18. Proton nuclear magnetic resonance measurement of p-boronophenylalanine (BPA): a therapeutic agent for boron neutron capture therapy. Zuo CS; Prasad PV; Busse P; Tang L; Zamenhof RG Med Phys; 1999 Jul; 26(7):1230-6. PubMed ID: 10435522 [TBL] [Abstract][Full Text] [Related]
19. Distribution of BPA and metabolic assessment in glioblastoma patients during BNCT treatment: a microdialysis study. Bergenheim AT; Capala J; Roslin M; Henriksson R J Neurooncol; 2005 Feb; 71(3):287-93. PubMed ID: 15735919 [TBL] [Abstract][Full Text] [Related]